An under-the-radar biotech finds FDA more receptive to an alternative to Covid vaccines

Taking stock of the drug industry, from the lab to the medicine chest

August 28, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | An under-the-radar biotech finds FDA more receptive to an alternative to Covid vaccines In this week's edition of "Adam's Biotech Scorecard," Adam looks at Invivyd's monoclonal antibody, as well as MoonLake's looming study readout. By Adam Feuerstein STAT+ | Health care giants are pushing hard for Congress to extend ACA insurance subsidies Enhanced Affordable Care Act subsidies that help millions of people buy cheaper health insurance will expire at the end of the year unless Congress acts. By Daniel Payne STAT+ | Inside the CDC director's ouster: Kennedy demanded acceptance of new vaccine policies; Susan Monarez refused Tense meetings, vaccine disputes, and phone calls to senators went on behind the scenes as Susan Monarez refused to 'rubber-stamp' proposals By Daniel Payne

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser